Menu

Study: Vaping Causes DNA Damage in Human Cells and Mice

New findings suggest that nicotine inhaled from e-cigarettes could contribute to cancer and heart disease, but critics warn that the data are too preliminary to draw such conclusions.

Jan 31, 2018
Ashley Yeager

FLICKR, VAPING 360Nicotine inhaled from e-cigarettes can damage DNA in mouse heart, lung, and bladder and in cultured human lung and bladder cells, a new study shows. The results, published Monday (January 29) in PNAS, suggest that vaping increases the risk of developing cancer and heart disease and reinforce the research showing e-cigarettes’ risks to human health.

The DNA changes were similar to those linked to secondhand smoke, study coauthor Moon-shong Tang of New York University tells The Guardian. Specifically, the team found that two mutagenic compounds develop in lung, bladder, and heart cells exposed to e-cigarette smoke. DNA-repair activity and the repair proteins XPC and OGG1/2 were reduced in the lung tissue of mice.

See “Swapping Cigarettes for Vaping

Critics caution that the mice in the study were exposed to higher levels of e-cigarette smoke than those who vape might inhale (although Bloomberg reports that, over 12 weeks, mice were exposed to a dose similar to what a human would intake after smoking e-cigarettes lightly for 10 years). Still, “this study shows nothing at all about the dangers of vaping,” Peter Hajek, director of the Wolfson Institute of Preventive Medicine's Tobacco Dependence Research Unit at Queen Mary University of London, notes in The Guardian. “It doesn’t show that vaping causes cancer.”

In the paper, Tang and his colleagues concede that “it takes decades for carcinogen exposure to induce cancer in humans, [so] for decades to come there will be no meaningful epidemiological study to address the carcinogenicity of [e-cigarette smoke].” Still, the levels of carcinogenic compounds are higher in the blood of vapers than nonsmokers, pointing to the increased risk of developing cancer.

The bottom line, Tang tells Bloomberg, is: “Don’t think a vapor is harmless.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.